Chi‐Chung Chan
Regend Therapeutics (China)(CN)
Publications by Year
Research Areas
Inflammatory mediators and NSAID effects, Estrogen and related hormone effects, Asthma and respiratory diseases, Synthesis of β-Lactam Compounds, Receptor Mechanisms and Signaling
Most-Cited Works
- → Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene(1999)2,185 cited
- → Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes(2005)490 cited
- → Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2(2001)457 cited
- → The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor(1999)427 cited
- → Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles(1999)398 cited
- → Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor(1997)326 cited
- → Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.(1995)313 cited
- → A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors(1996)281 cited
- → Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530(1998)271 cited
- → Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis(2002)266 cited